Prenetics Global (NASDAQ:PRE) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Prenetics Global (NASDAQ:PRE) from a sell rating to a hold rating in a research report report published on Saturday.

A number of other research firms also recently issued reports on PRE. Weiss Ratings reiterated a “sell (d-)” rating on shares of Prenetics Global in a research report on Friday, July 17th. Benchmark raised their price target on shares of Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $34.25.

Prenetics Global Stock Performance

Shares of PRE stock opened at $20.20 on Friday. The company has a market cap of $340.77 million, a P/E ratio of -4.86 and a beta of 0.26. The stock has a 50 day simple moving average of $19.05 and a two-hundred day simple moving average of $18.88. Prenetics Global has a fifty-two week low of $7.18 and a fifty-two week high of $23.63.

Prenetics Global (NASDAQ:PRE) last posted its quarterly earnings results on Tuesday, August 18th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.84) by $0.31. The firm had revenue of $46.49 million for the quarter, compared to analysts’ expectations of $49.85 million. Prenetics Global had a negative return on equity of 21.41% and a negative net margin of 47.43%. On average, research analysts predict that Prenetics Global will post -1.86 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Wells Fargo & Company MN bought a new stake in shares of Prenetics Global during the fourth quarter worth about $47,000. State of Wyoming acquired a new stake in shares of Prenetics Global in the 1st quarter worth about $48,000. JPMorgan Chase & Co. bought a new position in Prenetics Global in the 3rd quarter valued at about $65,000. Manatuck Hill Partners LLC bought a new position in Prenetics Global in the 4th quarter valued at about $170,000. Finally, T3 Companies LLC bought a new position in Prenetics Global in the 4th quarter valued at about $170,000. 25.01% of the stock is owned by institutional investors.

Key Stories Impacting Prenetics Global

Here are the key news stories impacting Prenetics Global this week:

• Positive Sentiment: IM8 reported 288% year-over-year revenue growth in the second quarter and Prenetics raised its FY 2026 IM8 revenue guidance to $220 million–$230 million. The company also initiated FY 2027 revenue guidance of at least $400 million, signaling strong expected demand and expansion. IM8 Q2 revenue growth and guidance article
• Positive Sentiment: Prenetics announced actress and producer Lily Collins as IM8’s global ambassador and a shareholder. Her audience of more than 33 million social-media followers could broaden IM8’s reach beyond elite sports and improve its access to female consumers. The company said it has already achieved positive consolidated adjusted free cash flow and expects to remain positive in the third quarter. Lily Collins IM8 partnership article
• Neutral Sentiment: Analyst forecasts are mixed. Sidoti raised its Q3 and Q4 2026 estimates but still projects a FY 2026 loss of $2.36 per share, while Zacks lowered its Q3 2026 and FY 2026 forecasts but expects stronger Q4 results and a narrower Q1 2027 loss. These revisions suggest near-term volatility as investors assess whether IM8’s growth can translate into sustained profitability.
• Negative Sentiment: Sidoti lowered its FY 2027 EPS forecast to a loss of $0.72 from a loss of $0.60 and reduced several 2027 quarterly estimates. Prenetics’ latest quarter also showed a negative net margin, and revenue was below consensus despite an EPS beat, underscoring execution and profitability concerns.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.